Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV +0.12%41 Days Payable is 24.64 as of Dec. 2025, which is 43% below its 10-year median of 43.13. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Bio View ranks worse than 90.31% on this metric.
Bio View's average Accounts Payable for the
six
months ended in Dec. 2025 was ₪0.72 Mil. Bio View's Cost of Goods Sold for the
six
months ended in Dec. 2025 was ₪5.35 Mil.
Hence, Bio View's Days Payable for the
six
months ended in Dec. 2025 was 24.64.
The historical rank and industry rank for Bio View's Days Payable or its related term are showing as below:
XTAE:BIOV'
s Days Payable Range Over the Past 10 Years
Min: 22.35 Med: 43.13 Max: 57.91
Current: 24.32
During the past 13 years, Bio View's highest Days Payable was 57.91. The lowest was 22.35. And the median was 43.13.
XTAE:BIOV's Days Payable is ranked worse than 90.31% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.76
vs XTAE:BIOV: 24.32
Bio View's Days Payable
declined
from Dec. 2024 (59.29) to Dec. 2025 (24.64).
It may suggest that Bio Viewaccelerated paying its suppliers.
The historical data trend for Bio View's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BIOV vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Bio View's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Days Payable distribution charts can be found below:
* The bar in red indicates where Bio View's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bio View's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a Days Payable of 24.64 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio View and its competitors. This is 43% below median its historical median of 43.13. Over the past decade, Bio View's Days Payable has ranged from 22.35 to 57.91. According to the industry distribution chart, Bio View ranks #718 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 90.3%.
Is Bio View's Days Payable too high?
Bio View's current Days Payable of 24.64 is 43% below median its 10-year median of 43.13. Over the past 10 years, this metric has ranged from a low of 22.35 to a high of 57.91. The Medical Devices & Instruments industry median Days Payable is 68.76. Bio View's value of 24.64 is 64.2% below this industry median. Based on the distribution chart, Bio View ranks #718 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #718 out of 795 companies for Days Payable. This places Bio View in the lower half of its industry. The industry median Days Payable is 68.76. Bio View's value of 24.64 is 64.2% below this benchmark. Historically, Bio View's own Days Payable has ranged from 22.35 to 57.91 over the past decade. While the company's 10-year median is 43.13 vs. the industry median of 68.76, Bio View has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.76, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio View's current Days Payable of 24.64 is 64.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio View and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio View's current Days Payable is 24.64, which is 43% below median its own 10-year median of 43.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current Days Payable is 24.64, which is 43% below median its 10-year median of 43.13 and 64.2% below the Medical Devices & Instruments industry median of 68.76. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current Days Payable is 24.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
Days Payable: 24.64 (43% below median its 10-year median of 43.13)
GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
Industry Position: 64.2% below the Medical Devices & Instruments median (#718 of 795)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
